Mary Ann Johnson

Title: Celebrating the Innovative Contributions of Inventor Mary Ann Johnson

Introduction: Mary Ann Johnson, an esteemed inventor based in West Point, Pennsylvania, has made significant contributions to the field of pharmaceuticals. With a portfolio of six patents, her work primarily focuses on innovative treatments for migraine. By integrating her extensive knowledge and experience, Mary Ann has developed crucial formulations that aim to enhance patient care for those suffering from this debilitating condition.

Latest Patents: Among her latest inventions are pharmaceutical formulations for the treatment of migraine, which highlight the administration of ubrogepant. Her patents provide crucial methodologies for the acute treatment of migraine with or without aura, especially for patients who face hepatic impairment, renal impairment, or those concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors. These innovations are a testament to her dedication to improving therapeutic outcomes for migraine sufferers.

Career Highlights: Throughout her career, Mary Ann has been associated with prominent organizations such as Merck Sharp & Dohme Corporation. Her extensive experience in the pharmaceutical industry has equipped her with the expertise necessary to drive innovation and develop effective treatment options.

Collaborations: Mary Ann Johnson has collaborated with several esteemed colleagues during her career. Notable coworkers include Leonardo Resende Allain and W Mark Eickhoff. These collaborations have enriched her research and contributed to her success as an inventor.

Conclusion: Mary Ann Johnson's commitment to pharmaceutical innovation has had a profound impact on migraine treatment. Her six patents demonstrate her skill and dedication to improving healthcare for countless individuals. As she continues to develop new solutions, her work inspires future generations of inventors and innovators in the pharmaceutical field.